The effectiveness of antihistamine and antileukotriene drugs in the treatment of irritable bowel syndrome with the reveled concomitant allergic conditions

Abstract

Objective — to rectify the histamine role in the pathogenesis of irritable bowel syndrome (IBS) and to establish the efficacy of antihistamine and antileukotriene drugs in the complex treatment of IBS patients.Materials and methods. The study was conducted in the years 2016 to 2017 on the basis of the Department of Internal Medicine N 1 of O. O. Bogomolets National Medical University. The examinations involved 150 IBS patients with the mean age 40.8 ± 2.1 years, from them 106 (72.6 %) women. Patients with the reveled concomitant allergic conditions (84 (56 %)) were divided into two groups. The first group (n = 40) received the standard basictherapy depending on the IBS sub-type, the second group (n = 44) received the additional combined anti-inflammatory treatment with Quifenadine (25 mg 3 times a day) in combination with Montelukast (10 mg once a day). The groups were matching by the mean age and gender ratio. The treatment efficacy was assessed after 1 month.Results. It has been shown that in IBS patients, histamine levels were significantly higher (р ≤ 0.05), and blood serum enzyme diaminoxidase levels (р ≤ 0.05) were lower, that may indicate the presence of histamine intolerance in some groups of patients. The additional administration of quifenadine and montelukast resulted not only in the significant reduction of allergic complaints, but also in the decrease in serum histamine level (р ≤ 0.05), increased treatment effectiveness of the IBS patients, in particular, significant reduction in the intensity of pain and diarrheal syndrome (р ≤ 0.001) and also increased indicators of the general health, vitality and physical condition of the patients (р ≤ 0.05).Conclusions. Montelukast, as well as the III generation antihistamines, may be a method of treatment of patinets with IBS and allergic conditions, but to provide the clinical recommendations, the additional and well designed trials should be conducted in other gastroenterological and allergological centers.